Evidence map›Paper›PMID 42086864›Full record

ArticleDiscover oncology2026

Case report of adult-type diffuse high-grade glioma IDH-wildtype subtype E with secondary spinal leptomeningeal dissemination, prolonged survival and literature review.

Adèle Meola, Romain Appay, Benoit Testud, Gregorio Petrirena, Chantal Campello, Maryline Barrié, Alexandre Bertucci, Didier Autran, Thomas Graillon, Kaissar Farah and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Adèle MeolaAP-HM, Neuro-Oncology Department, University Hospital Timone, 264 Rue Saint Pierre, 13005, Marseille, France. Meola.adele@iuct-oncopole.fr.
Romain AppayNeuropathology Department University Hospital Timone, Aix Marseille University, 13005, Marseille, France.
Benoit TestudAPHM, Neuroradiology Department, University Hospital Timone, 13005, Marseille, France.
Gregorio PetrirenaAP-HM, Neuro-Oncology Department, University Hospital Timone, 264 Rue Saint Pierre, 13005, Marseille, France.
Chantal CampelloAP-HM, Neuro-Oncology Department, University Hospital Timone, 264 Rue Saint Pierre, 13005, Marseille, France.
Maryline BarriéAP-HM, Neuro-Oncology Department, University Hospital Timone, 264 Rue Saint Pierre, 13005, Marseille, France.
Alexandre BertucciAP-HM, Neuro-Oncology Department, University Hospital Timone, 264 Rue Saint Pierre, 13005, Marseille, France.
Didier AutranAP-HM, Neuro-Oncology Department, University Hospital Timone, 264 Rue Saint Pierre, 13005, Marseille, France.
Thomas GraillonAP-HM, INSERM, MMG, Neurosurgery Department, Aix-Marseille University, University Hospital Timone, 13005, Marseille, France.
Kaissar FarahAP-HM, INSERM, MMG, Neurosurgery Department, Aix-Marseille University, University Hospital Timone, 13005, Marseille, France.
Laetitia PadovaniAP-HM, Radiotherapy Department, Aix-Marseille University, University Hospital Timone, 13005, Marseille, France.
Isabelle PougnetAP-HM, Radiotherapy Department, Aix-Marseille University, University Hospital Timone, 13005, Marseille, France.
Isabelle NanniOncobiology Department, Aix-Marseille University, University Hospital Timone, 13005, Marseille, France.
Olivier ChinotAP-HM, Neuro-Oncology Department, University Hospital Timone, 264 Rue Saint Pierre, 13005, Marseille, France.
Emeline TabouretAP-HM, Neuro-Oncology Department, University Hospital Timone, 264 Rue Saint Pierre, 13005, Marseille, France.
Vincent HarlayAP-HM, Neuro-Oncology Department, University Hospital Timone, 264 Rue Saint Pierre, 13005, Marseille, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesWe report the case of an adult-type diffuse glioma with spinal leptomeningeal dissemination, corresponding to a new molecularly methylation class, identified as "Adult-type diffuse high-grade glioma, IDH-wildtype, subtype E," using the Heidelberg Epignostix CNS Tumor Classifier v12.8.

methodsClinical, histo-molecular, cerebrospinal fluid analyses and neuro-radiological data were recorded.

resultsA 43-year-old man was diagnosed 5 years ago with a diffuse glioma and subsequent spinal leptomeningeal dissemination. He received radiochemotherapy based on temozolomide followed by monthly temozolomide (6 months) but relapsed 15 months later. After three additional therapeutic lines, bevacizumab was introduced, achieving a clinical and imaging response with subtotal regression of lesions. To date, glioblastoma remains under control, 5 years after diagnosis and 3 years after bevacizumab introduction. DISCUSSION: We describe an unusual prolonged response to bevacizumab in a new subtype of adult-type diffuse high-grade glioma, with spinal leptomeningeal dissemination. Despite frequent dreadful prognosis in patients treated for high-grade gliomas, there are rare long-term responder patients. This situation remains unclear, particularly in the context of spinal leptomeningeal dissemination. The identification of new subtypes could help differentiate between miscellaneous prognostic group. It would be relevant to consider these subgroups in future clinical trials.

Indexed as

BevacizumabGlioblastomaLong-term survivalMethylation profilingSpinal leptomeningeal dissemination

Identifiers

PMID42086864
PMCPMC13315373

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.